Liquid biopsy firm Thrive launches with $110M Series A round
The company has a 10,000-patient prospective trial with Geisinger fully enrolled to test CancerSEEK, a test developed at Johns Hopkins University.
Verve Therapeutics aims to tackle heart disease through gene editing
The company, partnered with Beam Therapeutics, Verily Life Sciences and academic institutions, plans to use gene editing to tackle coronary artery disease. However, experience with gene therapy indicates cost could be a hurdle.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Two new venture funds, two new women at the top
Welcome to the senior VC club. Julie Sunderland of Biomatics Capital and Tracy Saxton of Pivotal bioVenture Partners closed their first funds this week, bringing fresh perspectives to the life science investment game.